News

Ideas That Generate Results

There are a plethora of protein therapeutic products under the Phase III clinical trial development stage. The successful clinical trials of these products can revolutionize their usage and clinical applications. The most promising pipeline is for the monoclonal antibody products owing to the efficacy and specificity that they offer. These monoclonal antibodies are being researched for several disease applications. Primarily monoclonal antibodies are growing in the field of cancer due to their tumor specific targeting ability. Insulin products from Eli Lilly and Sanofi have also entered advanced phases of trials. Primarily aimed at haemophilia, these products can be expected to be of great therapeutics use for this blood disorder.
 
Constant investment by major pharma players in mAbs will continue to boost the Protein Therapeutics market which may reach the mark of US$ 165 Billion by 2018. According to our new research report, “Global Protein Therapeutics Market Outlook 2018”, the growth within the market can also be attributed to increasing disposable income of the individuals and better delivery modes that are being developed.
 
The report takes into account all the key aspects of the worldwide protein therapeutics market and projects the market during the period 2012-2018. It prudently analyzes all the industry segments in an effective manner by focusing on major players and products, recent developments, application support in terms of indications, geographical performance and last but not the least, current and future market size. Moreover, the report provides a brief summary of the recent trends that may have an impact on the future industry performance. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM654.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm